TGFB1 and neoplasm: For such patients, we found that administration of a combination therapy consisting of TGF-β blockade and anti-PD-L1 antibody reduced TGF-β signaling in stromal cells, promoted T cell infiltration into the tumor center and triggered robust antitumor immunity and tumor regression.